Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq drops as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
Spruce Biosciences, Inc. (SPRB) PT Lowered to $4 at Oppenheimer
March 14, 2024 9:11 AM EDTOppenheimer analyst Hartaj Singh lowered the price target on Spruce Biosciences, Inc. (NASDAQ: SPRB) to $4.00 (from $7.00) while maintaining a Outperform rating.
The analyst comments "Spruce (SPRB) announced top-line results from the CAHmelia-203 and CAHptain-205 studies of tildacerfont in adult and pediatric classic CAH,... More
